UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 20, 2018
IASO BIOMED, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of incorporation)
| | |
| | |
333-215083 | | 47-3474169 |
(Commission file number) | | (IRS employer identification no.) |
| | |
| | |
7315 East Peakview Avenue Centennial, Colorado | | 80111 |
(Address of principal executive offices) | | (Zip code) |
(720) 389-0650
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act of 1933, as amended, and ☐
Item 8.01 Other Events.
Effective August 20, 2018, IASO BioMed, Inc. (the “Registrant”) entered into an agreement for the purchase of 900,000 units, at a purchase price of $0.30 per unit, consisting of one share of common stock of the Registrant, par value $0.0001 per share, and one warrant to purchase one share of common stock at an exercise price of $0.05 per share with an expiration date of three years from the date of issuance, for total proceeds of $270,000. The sale of the units was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(c) promulgated thereunder.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
Exhibit No. | Description |
| |
99.1 | Form of Warrant. Filed herewith. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | | | |
| | | | IASO BIOMED, INC.. |
| | | |
Date: August 24, 2018 | | | | By: | | /s/ Richard M. Schell |
| | | | | | Richard M. Schell |
| | | | | | Chief Executive Officer |
3
